Amarantus BioScience Holdings, Inc., a biotechnology company committed to developing diagnostics in neurology and to advance therapeutic products in several areas such as neurology, ophthalmology, psychiatry and regenerative medicine, recently announced the formation of an Alzheimer’s disease Diagnostics Scientific Advisory Board (SAB). The company also designated three renowned experts in Alzheimer’s disease and neurological disorders as its first members: Paula T. Trzepacz, Jeffrey L. Cummings and Robert A. Stern. The SAB is expected to be expanded during the first six months of 2015.
Gerald E. Commissiong, the CEO and President of Amarantus, stated, “I am pleased to announce the appointments of such an esteemed trio of Alzheimer’s researchers to Amarantus Diagnostics’ inaugural Scientific Advisory Board.
“Following last week’s announcement of our exclusive option agreement with Georgetown University to license their suite of markers for Alzheimer’s disease, adding exciting lipidomic and exosome modalities to our cell cycle dysregulation LymPro Test® blood diagnostic, we are now positioned to corner the entire Alzheimer’s blood-based diagnostics marketplace, a potential $3 billion market opportunity. We are beginning with the $150 million Investigational Use Only (IUO) market by offering the world’s most extensive suite of markers to the pharmaceutical industry.”
Mr. Commissiong continued expressing how impressed he was with the “extensive neurobiology and neurotherapeutic experience of our inaugural members in Alzheimer’s disease given that we are now actively engaged in the marketing of our blood-based markers to the IUO market. They will be of great assistance as we work with pharmaceutical companies to improve their Alzheimer’s therapeutics development programs, which have had a disappointing 99.6% failure rate, in large part due to an inability to properly screen patients prior to study enrollment, as well as difficulty in monitoring the effectiveness of drug activity on disease-relevant biomarkers. Currently, the gold standard for Alzheimer’s diagnosis remains autopsy confirmation, with some incremental improvement such as recent advances in PET imaging. Ultimately, we are endeavoring to dramatically shift that paradigm, to the benefit of patients, their families, and world healthcare systems, by providing a simple and cost-effective tool to physicians that will greatly enhance their confidence in making an Alzheimer’s diagnosis and assist caregivers in managing this devastating disease with therapies we will have helped shepherd through clinical development.”